hVIVO plc functions as a contract research organization and pharmaceutical service provider, primarily dedicated to evaluating vaccines and antiviral medications. This is achieved through specialized human challenge clinical trials. The company extends its services to a varied clientele, encompassing major pharmaceutical and biotechnology firms, governmental bodies, and public health agencies. A significant aspect of its operations is a comprehensive array of human challenge study models. These cover conditions such as respiratory syncytial virus (RSV), influenza, human rhinovirus, asthma, malaria, chronic cough, and chronic obstructive pulmonary disease (COPD), with a COVID-19 model currently being developed. Additionally, hVIVO is constructing the 'Disease in Motion' platform, an extensive database focused on infectious disease progression. This platform uniquely integrates diverse datasets, including clinical, immunological, virological, and digital (wearable) biomarkers. The 'Disease in Motion' platform holds broad potential applications for various end-users, from large technology and wearables companies to pharmaceutical and biotech sectors. Further capabilities include offering pre-clinical and early clinical research services, sales and marketing support, and expertise in biometry, data management, and statistics to its European pharmaceutical clients. The company also delivers drug development consultancy, covering Chemistry, Manufacturing, and Controls (CMC), pharmacokinetics (PK), and medical writing for a range of European clients. Formerly known as Open Orphan Plc, the company changed its name to hVIVO plc in October 2022 and is headquartered in London, United Kingdom.